Biogen appoints former sanofi executive christopher viehbacher as ceo
Biogen appoints former sanofi executive christopher viehbacher as ceo"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new CEO on Thursday, opening a new chapter for one of the first and most successful biotechnology
firms but one that has struggled since the disastrous launch of the Alzheimer’s disease drug Aduhelm. Viehbacher, 62, will take the reins Monday, succeeding CEO Michel Vounatsos, who
announced his impending resignation in May. At Sanofi, Viehbacher was largely responsible for repositioning the staid French drugmaker and for deepening its partnership with the biotech firm
Regeneron Pharmaceuticals, a collaboration that resulted in the blockbuster autoimmune drug Dupixent, which generates more than $5 billion in annual sales and which Sanofi has forecast
could top $10 billion in annual sales. He ran the firm for six years. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE
— PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this
story subscribe to STAT+. Subscribe
Trending News
Prince William set to be ‘cold’ in Megxit review as Duke shares Queen’s ‘hard edge’The Duke of Cambridge will soon be back in the negotiation room with the Queen, Prince Charles and Prince Harry to discu...
In The Dictator's Shadow, Life | WFAE 90.7 - Charlotte's NPR News SourceIn The Dictator's Shadow, Life By Jeffrey Freymann-Weyr Published June 30, 2009 at 12:00 AM EDT Facebook Twitter LinkedI...
In Brief | Nature BiotechnologyBusiness and Regulatory News Published: September 2001 In Brief Nature Biotechnology volume 19, pages 801–803 (2001)Cite...
Letters to the Editor: Israel is fighting a crisis for its democracy. Will the U.S. do the same?To the editor: I am so impressed by the sustained and outraged demonstrations exhibited by Israel’s population in respon...
Great expectations? The next phase of the russo-ukrainian war – war on the rocksMichael Kofman joined Ryan for yet another conversation about the unfolding tragedy of the Russo-Ukrainian War. In this ...
Latests News
Biogen appoints former sanofi executive christopher viehbacher as ceoBiogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new CEO on Thursday, opening ...
In Brief | Nature BiotechnologyBusiness and Regulatory News Published: September 2001 In Brief Nature Biotechnology volume 19, pages 801–803 (2001)Cite...
Letters to the Editor: Israel is fighting a crisis for its democracy. Will the U.S. do the same?To the editor: I am so impressed by the sustained and outraged demonstrations exhibited by Israel’s population in respon...
Great expectations? The next phase of the russo-ukrainian war – war on the rocksMichael Kofman joined Ryan for yet another conversation about the unfolding tragedy of the Russo-Ukrainian War. In this ...
What Are The Types of Strokes and Their Treatments?Getty Images Facebook Twitter LinkedIn If you or someone you love has had a stroke, you’ve probably heard: Time is brain...